Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 5/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL951530 | 1.00 | BLM (0.44) | BLMNPSR1KDM4ECYP2D6CYP2C19 | |
| Sulfuric Acid SCHEMBL28092122 | 0.98 | BLM (0.42) | BLMNPSR1KDM4ECYP2D6CYP2C19 | |
| SCHEMBL27449362 | 0.93 | GRIN2D (0.40) | BLMNPSR1KDM4ECYP2D6CYP2C19 | |
| Sulfuric Acid SCHEMBL11558296 | 0.87 | GRIN2D (0.42) | BLMNPSR1KDM4ECYP2D6CYP2C19 | |
| SCHEMBL1793572 | 0.87 | — | — | |
| SCHEMBL34049 | 0.87 | — | — | |
| Urea SCHEMBL27941571 | 0.84 | GRIN2D (0.44) | BLMCYP2D6CYP2C19GRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL3193405 | 0.84 | — | — | |
| Sulfuric Acid SCHEMBL11565543 | 0.81 | GRIN2D (0.44) | BLMNPSR1KDM4ECYP2D6CYP2C19 | |
| Acetic Acid SCHEMBL28832296 | 0.80 | GRIN2D (0.41) | BLMCYP2C19GRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107892787-B | Heat dissipation plastic for noctilucent television and processing technology thereof | 义乌市添诚科技有限公司 | 2020-11-17 | — | — | CN | disclosed |
| US-7893210-B2 | For interleukin-4 and bovine pancreatic trypsin inhibitor (BPTI) previously solubilized in presence of guanidinium hydrochloride as chaotropic agent | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-22 | — | — | US | disclosed |
| EP-1453858-B1 | PROCESS FOR RENATURATION OF RECOMBINANT, DISULFIDE CONTAINING PROTEINS AT HIGH PROTEIN CONCENTRATIONS IN THE PRESENCE OF AMINES | BAYER SCHERING PHARMA AG (DE) | 2011-01-12 | — | — | EP | disclosed |
| US-20060116518-A1 | Novel phenanthridines | ALTANA PHARMA AG (DE) | 2006-06-01 | — | — | US | disclosed |
| US-20050014933-A1 | Process for renaturation of recombinant, disulfide containing proteins at high protein concentrations in the presence of amines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2005-01-20 | — | — | US | disclosed |
| EP-0693073-B1 | BICYCLIC ANSAMYCINS AND THEIR USE AS ANTITUMOR AGENTS | PFIZER (US) | 1998-06-03 | — | — | EP | disclosed |
| EP-0693073-A1 | BICYCLIC ANSAMYCINS AND THEIR USE AS ANTITUMOR AGENTS | PFIZER INC. (US) | 1996-01-24 | — | — | EP | disclosed |
| US-5387584-A | Bicyclic ansamycins | PFIZER INC. (US) | 1995-02-07 | — | — | US | disclosed |
| WO-1994022867-A1 | BICYCLIC ANSAMYCINS AND THEIR USE AS ANTITUMOR AGENTS | PFIZER INC. (US) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014933-A1 | Process for renaturation of recombinant, disulfide containing proteins at high protein concentrations in the presence of amines | SPR, P4HB, WIZ | BLM 1876/4885NPSR1 1654/4885KDM4E 4448/4885 |
| US-20060116518-A1 | Novel phenanthridines | PDE4A, PDE4B, PDE3A | BLM 1670/4885NPSR1 547/4885KDM4E 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.